title: Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression.
abstract: All mutations known to cause familial Alzheimer's disease (AD) act by increasing the levels of soluble beta-amyloid peptide (A beta), especially the longer form, A beta42. However, in vivo elevation of soluble A beta in sporadic AD has so far not been shown. In the present study, we used enzyme-linked immunosorbent assays specific for A beta42 and A beta40 to investigate cerebrospinal fluid from sporadic AD at different stages of disease severity, to clarify the roles of A beta42 and A beta40 during disease progression. We also evaluated three other groups--one group of patients with mild cognitive impairment who were at risk of developing dementia, a cognitively intact, nondemented reference group diagnosed with depression, and a perfectly healthy control group. We found that A beta42 is strongly elevated in early and mid stages of AD, and thereafter it declines with disease progression. On the contrary, A beta40 levels were decreased in early and mid stages of AD. The group of cognitively impaired patients and the depression reference group had significantly higher levels of A beta42 than the healthy control group, implying that A beta42 is increased not only in AD, but in other central nervous system conditions as well. Our data also point out the importance of having thoroughly examined control material. The initial increase and subsequent decrease of A beta42 adds a new biochemical tool to follow the progression of AD and might be important in the monitoring of therapeutics.
authors.affiliation: Karolinska Institutet, Department of Clinical Neuroscience and Family Medicine, Huddinge, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Jensen
authors.forename: J
authors.initials: J
authors.lastname: Schröder
authors.forename: M
authors.initials: M
authors.lastname: Blomberg
authors.forename: B
authors.initials: B
authors.lastname: Engvall
authors.forename: J
authors.initials: J
authors.lastname: Pantel
authors.forename: N
authors.initials: N
authors.lastname: Ida
authors.forename: H
authors.initials: H
authors.lastname: Basun
authors.forename: L O
authors.initials: LO
authors.lastname: Wahlund
authors.forename: E
authors.initials: E
authors.lastname: Werle
authors.forename: M
authors.initials: M
authors.lastname: Jauss
authors.forename: K
authors.initials: K
authors.lastname: Beyreuther
authors.forename: L
authors.initials: L
authors.lastname: Lannfelt
authors.forename: T
authors.initials: T
authors.lastname: Hartmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D016229:Amyloid beta-Peptides